Defensin (HBD-3) dosing & administration
Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
200 µg/mL applied to the wound, about 4 µg per dose (20 µL)
Frequency
Every 2 days in the study
Duration
Until wound healed (study setting)
HBD-3 is a research-only peptide with no human dosing protocol. This amount comes from a preclinical infected-diabetic-wound study where it was applied to the wound surface and sped up healing while lowering bacteria [6]. Human use has not been established.
Timing
Best time to take
Apply Defensin (HBD-3) to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, Defensin (HBD-3) is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
Defensin (HBD-3) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Defensin (HBD-3) is administered Topical application (research/wound care)—no injection required
Best sites
Storage
Before reconstitution
Store Defensin (HBD-3) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Defensin (HBD-3) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (varies by protocol)
As prescribed by your healthcare provider injection
Site: Topical application (research/wound care)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Defensin (HBD-3). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Local site irritation, Transient inflammatory response, Mild wound bed changes
Less common: Localized allergic reaction, Mild cytotoxicity at high concentrations
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Defensin (HBD-3)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Defensin (HBD-3) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Anionic polymers or surfactants — may complex with the cationic HBD-3 and neutralize activity through electrostatic interactions — Use with caution—discuss with your healthcare provider.
- High concentrations of divalent cations (Ca²⁺, Mg²⁺) in formulation — may affect peptide-membrane interactions at extreme concentrations — Use with caution—discuss with your healthcare provider.
- Proteolytic wound debridement enzymes (collagenase) applied simultaneously — may degrade the peptide at the application site despite its relative protease resistance — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Harder J, Bartels J, Christophers E, Schröder JM · 2001
Research supports defensin-hbd-3's antimicrobial effectiveness against a broad range of pathogens with minimal human toxicity.
Hoover DM, Wu Z, Tucker K, et al. · 2003
Research (2001) on defensin hbd 3 contributes important scientific knowledge about its biological and pharmacological properties.
Wu Z, Hoover DM, Yang D, Boulègue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W · 2003
Research (2003) demonstrates defensin hbd 3's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
Sass V, Schneider T, Wilmes M, Körner C, Tossi A, Novber N, Schwarz S, Żyła DS, Global Alliance, Hoerauf A · 2010
Research (2010) on defensin hbd 3 contributes important scientific knowledge about its biological and pharmacological properties.
Zhu C, Bao NR, Chen S, et al. · 2017
Study (2013) characterizes the biological activity and functional properties of defensin hbd 3.
Hirsch T, Spielmann M, Velander P, Zuhaili B, Bleiziffer O, Fossum M, Steinstraesser L, Yao F, Eriksson E · 2009
Preclinical infected diabetic wound model: 200 µg/mL hBD-3 in 20 µL of 0.01% acetic acid (about 4 µg per dose) applied topically every 2 days reduced bacterial load and promoted wound healing and angiogenesis.
Head to head
Defensin (HBD-3) compared
Want the full picture?
The complete Defensin (HBD-3) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.